Answers are grounded in this paper and cite their sources.
Chronic inflammatory or neuropathic pain are chronic syndromes poorly treated by commonly recommended systemic pharmacological therapies, partly due to dose-limiting side effects or adverse events. The use of topical therapeutics for chronic pain is growing and benefits from the reduced potential for adverse effects and the ability to target directly peripheral pathological processes. The current review identifies and describes the limitations of various commonly prescribed systemic pharmacological therapies for chronic inflammatory and neuropathic pain. It also justifies increased research to develop topical therapeutics for chronic pain, mainly localized inflammatory and neuropathic pain. The review discusses the various classes of topical treatments used for chronic pain, including agents that block sensory inputs; provide mechanism-based therapeutics; activate inhibitory systems; include combinations that produce multimodal therapeutic effects; and are targeted to mucosal tissues. It can be argued that current topical therapeutics for chronic pain rely too heavily on local anesthetics and capsaicinoids. More research is needed on multimodal topical therapies and/or targeted at the peripheral sources of pathology. Novel topical therapeutic development would also benefit from further research on topical co-drugs, drug-drug salts, cocrystal and hydrates, and ionic liquids.
No takes yet. Share an insight, caveat, or question.
Coderre et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: